Melatonin is the most widely purchased sleep supplement in the world. In the US it is now among the top five most commonly used supplements across all adult age groups.[1] For perimenopausal women dealing with sleep disruption, it is often one of the first things tried.

Understanding what melatonin actually does, and what it does not do, matters before deciding whether it belongs in your routine.

What Melatonin Is

Melatonin is a hormone produced by the pineal gland in response to darkness. As light levels fall in the evening, the suprachiasmatic nucleus (the brain's master circadian clock) signals the pineal gland to begin secretion. Melatonin rises through the evening, peaks between 2 and 4 AM, and falls before dawn as cortisol begins its morning rise.

Melatonin does not cause sleep directly. It is a darkness signal: a message to the body that nighttime has arrived and that the appropriate physiological processes for night should begin. The distinction explains both its genuine uses and its limitations.

How Melatonin Changes in Perimenopause

Melatonin production declines with age, beginning in the mid-40s and continuing into older age.[2] The decline is gradual rather than sudden. By the late perimenopausal years, melatonin secretion is lower than it was in a woman's 30s.

Estrogen also plays a role. It influences the activity of the enzyme (AANAT) involved in melatonin synthesis, and some research suggests that declining estrogen contributes to reduced melatonin amplitude on top of the age-related decline.[3] Postmenopausal women tend to have lower nocturnal melatonin peaks than younger premenopausal women, after controlling for age.

The practical effect: the darkness signal that should initiate sleep may be weaker and shorter in duration, making it harder to fall asleep and to maintain depth of sleep through the night.

What the Evidence Shows

Sleep onset

The strongest evidence for melatonin is reducing sleep latency, meaning the time it takes to fall asleep. A Cochrane-style meta-analysis by Ferracioli-Oda et al. (2013) of 19 randomised controlled trials found that melatonin reduced sleep onset latency by an average of seven minutes compared to placebo.[4] That is statistically significant and real, though modest. For someone lying awake 45 minutes before sleeping, seven fewer minutes is a small improvement.

Effects are more pronounced in circadian rhythm disorders (jet lag, shift work disorder, delayed sleep phase syndrome) where melatonin's role as a timing signal is directly relevant to the problem. For general insomnia, the evidence is weaker.

Perimenopausal sleep specifically

The evidence base in perimenopausal women is limited. A randomised trial by Toffol et al. (2014) found that melatonin supplementation (3 mg nightly) improved sleep quality on a composite sleep scale, with greater effects in those with more severe baseline disruption.[5] A smaller study by Bellipanni et al. (2001) found improvements in sleep and mood in postmenopausal women taking melatonin, though the study design had limitations.[6]

For sleep disrupted by vasomotor events waking women during the night, melatonin does not address the cause. Hot flashes and night sweats trigger arousals regardless of melatonin level; the problem is not difficulty initiating sleep but sleep being interrupted by a physiological event. Melatonin is more relevant to falling asleep in the first place than to the waking caused by night sweats.

Dose and Timing

Commercial products and clinical evidence diverge here.

Most over-the-counter melatonin products in the US contain doses between 5 mg and 10 mg per tablet. Some contain as much as 20 mg. The clinical evidence for sleep onset uses doses between 0.5 mg and 3 mg. Higher doses do not produce proportionally greater effects; they extend the duration of elevated melatonin, prolong suppression of core body temperature, and increase the likelihood of next-morning grogginess.[7]

Research on timing is consistent: melatonin taken 30 to 60 minutes before the intended sleep time is most effective for reducing sleep onset latency. Taking it earlier risks shifting the circadian rhythm rather than facilitating that night's sleep.

Dose guidance based on evidence: - Start with 0.5 to 1 mg, 30 to 60 minutes before bed - 3 mg is the upper end of doses with evidence for sleep onset effects in perimenopausal women - Doses above 3 mg are not supported by evidence for better outcomes and increase side-effect risk

In the UK, melatonin is a prescription-only medicine and cannot legally be sold over the counter, though imported products are widely available online. Circadin (2 mg prolonged-release) is available on NHS prescription for adults aged 55 and over with insomnia. GPs can prescribe off-label for younger patients where clinically appropriate.

In the US, melatonin is available over the counter as a dietary supplement without dose regulation.

Light Management as a First Step

Because melatonin is a darkness signal, the most targeted intervention for supporting natural production is not supplementation but light management.

Bright light in the morning (ideally outdoor light within an hour of waking, or a 10,000-lux light therapy lamp for 20 to 30 minutes) anchors the circadian clock and ensures melatonin onset occurs at the appropriate time in the evening.[8]

Reduced blue-spectrum light in the evening (from screens, LED overhead lighting) delays melatonin onset. Screen filter settings reduce but do not eliminate this effect; dimming overall light levels and reducing screen use in the 90 minutes before bed produces more consistent benefit.[9]

These interventions work with the same biological system that melatonin supplementation is attempting to influence. For women whose sleep difficulty is primarily about falling asleep rather than vasomotor waking, correcting light exposure is the more targeted first step.

When Melatonin Helps Most

Melatonin at low doses (0.5 to 3 mg) is a reasonable option for:

  • Difficulty falling asleep at the beginning of the night, particularly if sleep onset feels later than it should be
  • Jet lag recovery (well-evidenced, with timing specific to direction of travel)
  • Shift workers rotating between day and night shifts

It is less likely to help with:

  • Sleep disrupted by vasomotor events once it has started
  • Inability to return to sleep after waking in the early hours
  • Non-restorative sleep that is not fragmented

For vasomotor-disrupted sleep, treating the vasomotor symptoms is the effective path. HRT is the most evidence-based option; non-hormonal alternatives exist for those who cannot use it.

Safety

Melatonin at standard doses (0.5 to 5 mg) has a good short-term safety profile. The main documented side effects at higher doses are next-morning sedation, vivid or disturbing dreams, and headache. It is not habit-forming and does not suppress endogenous melatonin production with regular use at standard doses.[10]

Long-term safety data are limited. Most guidelines recommend using the lowest effective dose for the shortest necessary period rather than indefinite nightly use.

Melatonin may interact with anticoagulants (warfarin), immunosuppressants, and diabetes medications. If you take any regular prescription medication, mention melatonin use to your prescriber.

References

[1] National Institutes of Health. (2022). National Health Interview Survey: Use of complementary health approaches in the US. NCCIH. https://www.nccih.nih.gov/research/statistics

[2] Touitou, Y. (2001). Human aging and melatonin: Clinical relevance. Experimental Gerontology, 36(7), 1083–1100. https://doi.org/10.1016/s0531-5565(01)00120-6

[3] Okatani, Y., Morioka, N., Wakatsuki, A. (2000). Changes in nocturnal melatonin secretion in perimenopausal women: Correlation with endogenous estrogen concentrations. Journal of Pineal Research, 28(2), 111–118. https://doi.org/10.1034/j.1600-079x.2000.280207.x

[4] Ferracioli-Oda, E., Qawasmi, A., Bloch, M. H. (2013). Meta-analysis: Melatonin for the treatment of primary sleep disorders. PLOS ONE, 8(5), e63773. https://doi.org/10.1371/journal.pone.0063773

[5] Toffol, E., Kalleinen, N., Urrila, A. S., Himanen, S. L., Porkka-Heiskanen, T., Polo-Kantola, P. (2014). The relationship between mood and sleep in different female reproductive states. BMC Psychiatry, 14, 177. https://doi.org/10.1186/1471-244X-14-177

[6] Bellipanni, G., Bianchi, P., Pierpaoli, W., Bulian, D., Ilyia, E. (2001). Effects of melatonin in perimenopausal and menopausal women: A randomized and placebo controlled study. Experimental Gerontology, 36(2), 297–310. https://doi.org/10.1016/s0531-5565(00)00217-5

[7] Zhdanova, I. V., Wurtman, R. J., Lynch, H. J., et al. (1995). Sleep-inducing effects of low doses of melatonin ingested in the evening. Clinical Pharmacology and Therapeutics, 57(5), 552–558. https://doi.org/10.1016/0009-9236(95)90040-3

[8] Duffy, J. F., Czeisler, C. A. (2009). Effect of light on human circadian physiology. Sleep Medicine Clinics, 4(2), 165–177. https://doi.org/10.1016/j.jsmc.2009.01.004

[9] Chang, A. M., Aeschbach, D., Duffy, J. F., Czeisler, C. A. (2015). Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness. Proceedings of the National Academy of Sciences, 112(4), 1232–1237. https://doi.org/10.1073/pnas.1418490112

[10] Besag, F. M. C., Vasey, M. J., Lao, K. S. J., Wong, I. C. K. (2019). Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: A systematic review. CNS Drugs, 33(12), 1167–1186. https://doi.org/10.1007/s40263-019-00680-w